Bio-Path (BPTH) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 22, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Central Index Key	1,133,818
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 34,842,973
Trading Symbol	BPTH
Entity Common Stock, Shares Outstanding		11,340,756

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 5,965	$ 9,375
Prepaid drug product for testing	1,117	376
Other current assets	353	902
Total current assets	7,435	10,653
Fixed assets
Furniture, fixtures & equipment	984	708
Less accumulated depreciation	(330)	(94)
Property, Plant and Equipment, Net	654	614
Other assets
Technology licenses	2,500	2,500
Less accumulated amortization	(1,731)	(1,571)
Intangible Assets, Net (Excluding Goodwill), Total	769	929
Total Assets	8,858	12,196
Current liabilities
Accounts payable	52	69
Accrued expenses	739	969
Deferred revenue	0	12
Total current liabilities	791	1,050
Warrant liability	0	2,906
Total Liabilities	791	3,956
Shareholders’ equity
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $.001 par value; 200,000 shares authorized; 11,339 and 9,564 shares issued and outstanding, respectively	11	10
Additional paid in capital	47,213	40,364
Accumulated deficit	(39,157)	(32,134)
Total shareholders’ equity	8,067	8,240
Total Liabilities & Shareholders’ Equity	$ 8,858	$ 12,196

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000	10,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000	200,000
Common Stock, shares issued	11,339	9,564
Common Stock, shares outstanding	11,339	9,564

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 37	$ 13
Operating expense
Research and development	5,480	5,474
General and administrative	3,523	3,014
Total operating expense	9,003	8,488
Net operating loss	(8,966)	(8,475)
Other income (loss)
Change in fair value of warrant liability	2,374	1,713
Loss on extinguishment of warrant liability	(440)	0
Interest income	9	12
Total other income	1,943	1,725
Net loss	(7,023)	(6,750)
Loss per share
Deemed dividend related to warrant conversion	(1,038)	0
Net loss attributable to common stockholders	$ (8,061)	$ (6,750)
Net loss per share, basic and diluted	$ (0.8)	$ (0.73)
Basic and diluted weighted average number of common shares outstanding	10,081	9,270

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities
Net loss	$ (7,023)	$ (6,750)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	160	161
Depreciation	251	43
Stock-based compensation	793	784
Change in fair value of warrant liability	(2,374)	(1,713)
Loss on extinguishment of warrant liability	440	0
(Increase) decrease in assets
Prepaid drug product for testing	(741)	184
Other current assets	549	(723)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	0	(146)
Deferred revenue	(12)	12
Net cash used in operating activities	(7,957)	(8,148)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(538)	(338)
Net cash used in investing activities	(538)	(338)
Cash flow from financing activities
Net proceeds from sale of common stock	3,567	9,007
Net proceeds from exercise of warrants	1,518	0
Net cash provided by financing activities	5,085	9,007
Net increase (decrease) in cash	(3,410)	521
Cash, beginning of year	9,375	8,854
Cash, end of year	5,965	9,375
Non-cash financing activities
Warrants transferred to equity upon modification	797	0
Conversion of warrant liability to equity	175	0
Capital expenditures included in accrued expense	$ 0	$ 247

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Additional Paid in Capital Shares to be Issued	Accumulated Deficit
Beginning Balance at Dec. 31, 2015	$ 9,818	$ 9	$ 35,193	$ 0	$ (25,384)
Beginning Balance (in shares) at Dec. 31, 2015		8,976
Issuance of common stock, net of fees	4,388	$ 1	4,387
Issuance of common stock, net of fees (in shares)		588
Stock-based compensation	784		784
Net loss	(6,750)				(6,750)
Ending Balance at Dec. 31, 2016	8,240	$ 10	40,364	0	(32,134)
Ending Balance (in shares) at Dec. 31, 2016		9,564
Issuance of common stock, net of fees	3,567	$ 1	3,566
Issuance of common stock, net of fees (in shares)		1,333
Exercise of warrants	1,518	$ 0	1,518
Exercise of warrants (in shares)		442
Warrants transferred to equity upon modification	797		797
Conversion of warrant liability to equity	175		175
Stock-based compensation	793		793
Deemed dividend related to warrant modification	(1,038)		(1,038)
Modification of warrant exercise price	1,038		1,038
Net loss	(7,023)				(7,023)
Ending Balance at Dec. 31, 2017	$ 8,067	$ 11	$ 47,213	$ 0	$ (39,157)
Ending Balance (in shares) at Dec. 31, 2017		11,339

Organization and Business

Organization and Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business The Company is a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery of antisense drug substances for target specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize ® in vivo ® Using DNAbilize ® Our second drug candidate, Liposomal Bcl2 (“BP1002”), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. We are currently preparing an Investigational New Drug (IND) application for BP1002 in addition to completing additional IND enabling studies. We intend to initiate a Phase I clinical trial of BP1002 in refractory or relapsed lymphoma patients once we receive approval from the FDA. Our third drug candidate, Liposomal Stat3 (“BP1003”), targets the Stat3 protein and is currently in preclinical development in a pancreatic patient-derived tumor model. Previous preclinical models have shown BP1003 to successfully penetrate pancreatic tumors and to significantly enhance the efficacy of standard frontline treatments. We intend to initiate IND enabling studies of BP1003 in 2018. Bio-Path Subsidiary was founded in May 2007 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. In June 2015, the Company established an “at the market” (“ATM”) program through which it may offer and sell up to $ 25.0 In June 2016, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain healthcare focused institutional investors pursuant to which the Company agreed to sell an aggregate of 588,235 294,118 10.0 25,000 9.3 0.3 On May 21, 2017, the Company entered into Warrant Exercise Agreements (the “Exercise Agreements”) with certain holders (the “Exercising Holders”) of the 2016 Warrants and warrants to purchase up to 250,000 441,176 430,000 3.80 11,176 6.00 1.5 On June 13, 2017, the Company entered into amendments (the “Warrant Amendments”) with holders (the “Holders”) of the remaining 2016 Warrants, which amended the terms of their 2016 Warrants exercisable for 127,941 The Exercise Agreements for the 2014 Warrants resulted in the holders receiving $ 1.0 0.4 0.2 On November 3, 2017, we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell an aggregate of 1,333,333 666,667 4.0 16,000 3.6 On February 8, 2018, we effected a reverse stock split of our outstanding shares of common stock at a ratio of 1-for-10, and our common stock began trading on the split-adjusted basis on The Nasdaq Capital Market at the commencement of trading on February 9, 2018. All common stock share and per share amounts in this Annual Report on Form 10-K have been adjusted to give effect to the 1-for-10 reverse stock split, retrospectively. As of December 31, 2017, the Company had $ 6.0 9.4 As the Company has not begun its planned principal operations of commercializing a product candidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirement to secure additional funding, the outcome of the Company’s clinical trials, and failing to operationalize the Company’s current drug candidates before another company develops similar products.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies ® 50,000 50,000 250,000 5.7 9.4 9.1 Furniture, fixtures and equipment 0.3 43,000 The estimated useful lives are as follows: Computers and equipment – 3 Furniture and fixtures – 7 Scientific equipment – 7 Leasehold improvements – Lesser of useful life or lease term Major additions and improvements are capitalized, while costs for minor replacements, maintenance, and repairs that do not increase the useful life of an asset are expensed as incurred. 0.8 2.5 1.7 0.2 0.9 2.5 1.6 The Company estimates its clinical trial expense accrual each period based on a cost per patient calculation which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of the study and clinical study report costs. These services are performed by the Company’s third-party clinical research organizations, laboratories and clinical investigative sites. The expense accrual is recorded in research and development expense each period. Amounts that have been prepaid in advance of work performed are recorded in other current assets. For both the years ended December 31, 2017 and 2016, we had $ 5.5 562,041 1,277,784 544,167 595,118 The Company has experienced significant losses since its inception, including net losses of $ 7.0 6.8 39.2 6.0 The Company’s available cash at December 31, 2017 will not be sufficient to fund liquidity and capital expenditure requirements for the next twelve months from the date of issuance of these financial statements. The Company expects to continue to incur net losses for the foreseeable future in connection with its ongoing activities, including conducting clinical trials, manufacturing development and seeking regulatory approval of its drug candidates, prexigebersen, BP1002 and BP1003. Accordingly, the Company will continue to require substantial additional capital to fund its projected operating requirements. Such additional capital may not be available when needed or on terms favorable to the Company. In addition, the Company may seek additional capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for our current and future operating plan. There can be no assurance that the Company will be able to continue to raise additional capital through the sale of securities in the future. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, financial condition and future prospects. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. In February 2016, the FASB issued ASU No. 2016-02, Leases In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11 , Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Management has reviewed all other recently issued pronouncements and has determined they will have no material impact on the Company’s consolidated financial statements.

Prepaid Drug Product for Testin

Prepaid Drug Product for Testing	12 Months Ended
	Dec. 31, 2017
Prepaid Drug Product For Testing [Abstract]
Prepaid Drug Product for Testing	3. Prepaid Drug Product for Testing Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company made payments to its contract drug manufacturing and raw material suppliers totaling $ 0.4 1.1

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	4. Other Current Assets As of December 31, 2017, Other Current Assets included prepaid expenses of $ 0.4 0.2 0.1 0.1 0.9

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure	5. Property and Equipment December 31, Estimated Useful Lives 2017 2016 (in years) (in thousands) Leasehold improvements 2 to 3 $ 432 $ 393 Computers and office equipment 3 63 77 Furniture and fixtures 7 46 46 Scientific equipment 7 443 192 Total 984 708 Less: Accumulated depreciation (330) (94) Net property and equipment $ 654 $ 614

Accounts Payable

Accounts Payable	12 Months Ended
	Dec. 31, 2017
Accounts Payable Disclosure [Abstract]
Accounts Payable	6. Accounts Payable As of December 31, 2017, Current Liabilities included accounts payable of $ 0.1 0.1

Accrued Expense

Accrued Expense	12 Months Ended
	Dec. 31, 2017
Accrued Liabilities [Abstract]
Accrued Expense	7. Accrued Expense As of December 31, 2017, Current Liabilities included accrued expenses of $ 0.7 0.4 0.1 0.1 0.1 1.0 0.4 0.2 0.2 0.1 0.1

Warrant Liability

Warrant Liability	12 Months Ended
	Dec. 31, 2017
Derivative Liability [Abstract]
Warrant Liability	8. Warrant Liability In connection with the 2016 Registered Direct Offering, the Company issued warrants to purchase up to 294,118 23.00 25,000 24.60 Due to this provision and in accordance with ASC 480-10 (Distinguishing Liabilities from Equity), the 2016 Warrants were classified as a liability and recorded at fair value as calculated using the Binomial Lattice Model. The estimated fair value of the Warrant Liability for the 2016 Warrants on the closing date, July 5, 2016, was $ 4.6 As of December 31, 2017, and December 31, 2016, the fair values of the Warrant Liability were none and $ 2.9 2.4 1.7 0.4 0.2

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the 2016 Warrants on a recurring basis to determine the fair value of the liability. ASC 820 also establishes a hierarchy categorizing inputs into three levels used to measure and disclose fair value. The hierarchy gives the highest priority to quoted prices available in active markets and the lowest priority to unobservable inputs. An explanation of each level in the hierarchy is described below: Level 1 – Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date Level 2 – Quoted prices in markets that are not active or inputs which are either directly or indirectly observable Level 3 – Unobservable inputs for the instrument requiring the development of assumptions by the Company The Company’s Warranty Liability was extinguished as of June 30, 2017 (See Note 1). The following table summarizes the Company’s 2016 Warrants measured at fair value within the hierarchy on a recurring basis as of December 31, 2016: Fair Value Measurements at Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ - $ - $ 2,906 $ 2,906 The following table summarizes changes to the fair value of the Level 3 2016 Warrants for the year ended December 31, 2017: Fair Value of (in thousands) Balance at December 31, 2016 $ 2,906 Change in fair value (2,374 ) Extinguished (357 ) Reclassified to equity (175 ) Balance at December 31, 2017 $ - The following table summarizes changes to the fair value of the Level 3 2016 Warrants for the year ended December 31, 2016: Fair Value of (in thousands) Balance at December 31, 2015 $ - Issuance 4,619 Change in fair value (1,713 ) Balance at December 31, 2016 $ 2,906 The Company utilized the Binomial Lattice Model for estimating the fair value of the 2016 Warrants using the following assumptions on the reclassification dates of June 13, 2017 and May 21, 2017 and as of December 31, 2016: As of As of As of Risk-free interest rate 1.51 % 1.78 % 1.93 % Expected volatility 88 % 89 % 98 % Expected term in years 4.6 4.6 5.0 Dividend yield - % - % - %

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Issuances of Common Stock On November 3, 2017, we entered into a securities purchase agreement with certain investors pursuant to which we agreed to sell an aggregate of 1,333,333 shares of our common stock and warrants to purchase up to 666,667 shares of our common stock for gross proceeds of approximately $4.0 million under the 2017 Registration Statement. We also issued warrants to purchase up to 16,000 shares of common stock in a private placement to Roth Capital Partners, LLC as compensation for its services as a placement agent in connection with the 2017 Registered Direct Offering. The 2017 Registered Direct Offering closed on November 6, 2017. The net proceeds to the Company from the 2017 Registered Direct Offering, after deducting the placement agent’s fees and expenses and our offering expenses, and excluding the proceeds, if any, from the exercise of the warrants issued in the offering, were approximately $3.6 million. Warrant Exercises Stockholders’ Equity totaled $8.1 million as of December 31, 2017 compared to $8.2 million as of December 31, 2016. There were 11,339,032 shares of common stock issued and outstanding as of December 31, 2017. There were no preferred shares outstanding as of December 31, 2017.

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Plans	11. Stock-Based Compensation Plan The 2017 Plan Stock option awards granted for the years 2017 and 2016 were estimated to have a weighted average fair value per share of $6.00 and $20.90, respectively. The fair value calculation is based on stock options granted during the year using the Black-Scholes option-pricing model on the date of grant. In addition, for all stock options granted, exercise price was determined based on the fair market value as determined by the closing stock price at the date of the grant. 2017 2016 Risk-free interest rate 2.06% 1.37% Expected volatility 99% 109% Expected term in years 6.1 6.1 Dividend yield -% -% The Company determines the expected term of its stock option awards using the simplified method based on the weighted average of the length of the vesting period and the term of the exercise period. Expected volatility is determined by the volatility of the Company’s historical stock price over the expected term of the grant. The risk-free interest rate for the expected term of each option granted is based on the U.S. Treasury yield curve in effect at the time of grant. Weighted Weighted- Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value (per share) (in years) Year Ended December 31, 2017 Outstanding at December 31, 2016 707 $ 13.30 5.2 $ 2,241 Granted 68 7.50 9.3 Forfeited (87 ) 16.50 Expired (46 ) 21.30 Outstanding at December 31, 2017 642 $ 11.60 4.0 $ - Vested and expected to vest December 31, 2017 627 $ 11.50 3.8 $ - Exercisable at December 31, 2017 562 $ 10.70 3.3 $ - The aggregate intrinsic value represents the total pretax intrinsic value (the difference between the Company’s closing stock price on December 31, 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2017. This amount changes based on the fair market value of the Company’s stock. Weighted Weighted- Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value (per share) (in years) Year Ended December 31, 2016 Outstanding at December 31, 2015 575 $ 10.50 5.3 $ 1,972 Granted 132 25.40 9.3 Exercised - - Forfeited - - Outstanding at December 31, 2016 707 $ 13.30 5.2 $ 2,241 Vested and expected to vest December 31, 2016 673 $ 12.70 5.0 $ 2,239 Exercisable at December 31, 2016 544 $ 10.10 4.1 $ 2,236 The aggregate intrinsic value represents the total pretax intrinsic value (the difference between the Company’s closing stock price on December 31, 2016 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2016. This amount changes based on the fair market value of the Company’s stock. Stock-Based Compensation Expense

Warrants

Warrants	12 Months Ended
	Dec. 31, 2017
Derivative Financial Instruments Indexed to, and Potentially Settled in, Entity's Own Stock [Abstract]
Warrants	12. Warrants Warrants Outstanding Warrants Exercisable Weighted Average Weighted Weighted Remaining Average Average Number Contractual Exercise Number Exercise Year Issued Outstanding Life Price Exercisable Price (in years) (per share) (per share) 2008 1 0.3 $ 9.00 1 $ 9.00 2014 25 1.1 47.40 25 47.40 2016 (Note 10) 128 4.0 23.30 128 23.30 2017 (Note 10) 1,124 4.7 $ 5.10 1,108 5.10 1,278 4.5 $ 7.70 1,262 $ 7.80

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Technology License 0.1 Operating Lease 0.1 In April 2016, the Company entered into a three-year lease agreement for lab space located in Bellaire, Texas. The term of lease began on May 1, 2016 and terminates on April 30, 2019 and will require Bio-Path to pay $ 2,500 For the Year (in thousands) 2018 116 2019 61 Total $ 177 Drug Supplier Project Plan 1.1 1.6 1.0 0.4 0.2 1.2

Benefit Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2017
Compensation and Retirement Disclosure [Abstract]
Compensation and Employee Benefit Plans	Benefit Plan The Company initiated a contribution savings plan under Section 401(k) of the Internal Revenue Code in 2016. Under the plan, all eligible employees may contribute up to the statutory allowable amount governed by the Internal Revenue Service for any calendar year. We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of each employee’s base salary up to the allowable amount which is fully vested on the date the matching contributions are made. For the years ended December 31, 2017 and 2016, matching contributions totaled $ 47,000 48,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes At December 31, 2017, the Company had a net operating loss carryforward for federal income tax purposes of $ 35.8 2026 1.5 2028 In assessing the ability to realize its deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers evidence such as the reversal of deferred tax liabilities, projected future results of operations, and tax planning strategies in making this assessment. Based upon the level of historical taxable income, significant book losses during the current and prior periods, and projections for future results of operations over the periods in which the deferred tax assets are deductible, among other factors, management continues to conclude that the Company does not meet the “more likely than not” requirement of ASC 740 in order to recognize deferred tax assets. As such, a valuation allowance has been recorded to offset the Company’s net deferred tax assets at December 31, 2017. The Company recorded a decrease in the valuation allowance of $ 1.4 On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “2017 Tax Act”). The 2017 Tax Act significantly changes corporate income tax laws in the U.S. including reducing the corporate income tax rate from a maximum of 35% to a flat rate of 21%, effective January 1, 2018. As a result of the reduction in the corporate income tax rate under the 2017 Tax Act, an adjustment has been recorded to the deferred tax asset of $4.9 million. Due to the uncertainty surrounding the realization of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance on its deferred tax assets at December 31, 2017 and 2016. The changes in the valuation allowance were decreases of $9.5 million and $11.0 million for the years ended December 31, 2017 and 2016, respectively. December 31, 2017 2016 (in thousands) Deferred tax assets – non-current Accrued bonuses $ - $ - Accrued vacation 17 32 Net operating loss (NOL) carryover 7,516 9,166 Technology licenses amortization 36 60 Research & development tax credits 1,542 1,259 Share based expense 387 443 Other 5 9 Fixed asset depreciation 15 - Total deferred tax asset 9,518 10,969 Less: valuation allowance (9,518) (10,965) Net deferred tax asset - 4 Deferred tax liability- non-current - (4) Net deferred tax asset $ - $ - 34 December 31, 2017 2016 2015 (in thousands) Loss before income taxes $ (7,023) $ (6,750) $ (5,467) Tax (benefit) statutory tax rate (2,388) (2,295) (1,859) Effects of: Exclusion of incentive stock option expense 86 117 89 R&D tax credits (283) (252) (132) Increase (decrease) in valuation allowance (1,447) 3,001 1,899 FMV of warrants (658) (582) - Prior year adjustments 5 6 - Carryforward adjustment (252) 5 3 Rate change on net deferred tax asset 4,937 - - Provision for income taxes $ - $ - $ - As of December 31, 2017, the Company had no unrecognized income tax benefits. The Company’s policy for classifying interest and penalties associated with unrecognized income tax benefits is to include such items as tax expense. No interest or penalties have been recorded as of the year ended December 31, 2017, and no interest or penalties have been accrued as of December 31, 2017 and 2016. The Company’s open years for Internal Revenue Service (IRS) examination purposes due to normal statute of limitation are 2014, 2015 and 2016. However, since the Company has operating loss carryforwards, the IRS has the ability to make adjustments to items that originate in a year otherwise barred by the statute of limitations under Section 6501 of the Internal Revenue Code of 1986, as amended (the “code”), in order to redetermine tax for an open year to which those items are carried. Therefore, in a year in which a net operating loss deduction was claimed, the IRS may examine the year in which the net operating loss was generated and adjust it accordingly for purposes of assessing additional tax in the year the net operating loss was claimed. The Company is not currently under examination by the IRS or any other taxing authorities.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Event On February 8, 2018, we effected a reverse stock split of our outstanding shares of common stock at a ratio of 1-for-10, and our common stock began trading on the split-adjusted basis on The Nasdaq Capital Market at the commencement of trading on February 9, 2018 (See Note 1

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation —
Revenue Recognition	Revenue Recognition ® 50,000 50,000
Cash and Cash Equivalents	Cash and Cash Equivalents —
Concentration of Credit Risk	Concentration of Credit Risk 250,000 5.7 9.4 9.1
Furniture, fixtures and equipment	Furniture, fixtures and equipment 0.3 43,000 The estimated useful lives are as follows: Computers and equipment – 3 Furniture and fixtures – 7 Scientific equipment – 7 Leasehold improvements – Lesser of useful life or lease term Major additions and improvements are capitalized, while costs for minor replacements, maintenance, and repairs that do not increase the useful life of an asset are expensed as incurred.
Long-Lived Assets	Long Lived Assets
Intangible Assets	Intangible Assets/Impairment of Long-Lived Assets 0.8 2.5 1.7 0.2 0.9 2.5 1.6
Research and Development Costs	Research and Development Costs — The Company estimates its clinical trial expense accrual each period based on a cost per patient calculation which is derived from estimated start-up costs, clinical trial costs based on the number of patients and length of the study and clinical study report costs. These services are performed by the Company’s third-party clinical research organizations, laboratories and clinical investigative sites. The expense accrual is recorded in research and development expense each period. Amounts that have been prepaid in advance of work performed are recorded in other current assets. For both the years ended December 31, 2017 and 2016, we had $ 5.5
Stock-Based Compensation	Stock-Based Compensation —
Net Loss Per Share	Net Loss Per Share 562,041 1,277,784 544,167 595,118
Use of Estimates	Use of Estimates —
Income Tax	Income Taxes —
Liquidity	Liquidity The Company has experienced significant losses since its inception, including net losses of $ 7.0 6.8 39.2 6.0 The Company’s available cash at December 31, 2017 will not be sufficient to fund liquidity and capital expenditure requirements for the next twelve months from the date of issuance of these financial statements. The Company expects to continue to incur net losses for the foreseeable future in connection with its ongoing activities, including conducting clinical trials, manufacturing development and seeking regulatory approval of its drug candidates, prexigebersen, BP1002 and BP1003. Accordingly, the Company will continue to require substantial additional capital to fund its projected operating requirements. Such additional capital may not be available when needed or on terms favorable to the Company. In addition, the Company may seek additional capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for our current and future operating plan. There can be no assurance that the Company will be able to continue to raise additional capital through the sale of securities in the future. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, financial condition and future prospects.
Recent Accounting Pronouncements	Recent Accounting Pronouncements — In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. In February 2016, the FASB issued ASU No. 2016-02, Leases In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting In July 2017, the FASB issued ASU No. 2017-11 , Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Management has reviewed all other recently issued pronouncements and has determined they will have no material impact on the Company’s consolidated financial statements.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	The following table summarizes property and equipment as of December 31, 2017 and 2016: December 31, Estimated Useful Lives 2017 2016 (in years) (in thousands) Leasehold improvements 2 to 3 $ 432 $ 393 Computers and office equipment 3 63 77 Furniture and fixtures 7 46 46 Scientific equipment 7 443 192 Total 984 708 Less: Accumulated depreciation (330) (94) Net property and equipment $ 654 $ 614

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Fair Value Measurements at Level 1 Level 2 Level 3 Total Liabilities: Warrant liability $ - $ - $ 2,906 $ 2,906
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation	Fair Value of (in thousands) Balance at December 31, 2016 $ 2,906 Change in fair value (2,374) Extinguished (357) Reclassified to equity (175) Balance at December 31, 2017 $ - The following table summarizes changes to the fair value of the Level 3 2016 Warrants for the year ended December 31, 2016: Fair Value of (in thousands) Balance at December 31, 2015 $ - Issuance 4,619 Change in fair value (1,713) Balance at December 31, 2016 $ 2,906
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	As of As of As of December 31, 2016 Risk-free interest rate 1.51 % 1.78 % 1.93 % Expected volatility 88 % 89 % 98 % Expected term in years 4.6 4.6 5.0 Dividend yield - % - % - %

Stock-Based Compensation and Pl

Stock-Based Compensation and Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Weighted Weighted- Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value (per share) (in years) Year Ended December 31, 2017 Outstanding at December 31, 2016 707 $ 13.30 5.2 $ 2,241 Granted 68 7.50 9.3 Forfeited (87) 16.50 Expired (46) 21.30 Outstanding at December 31, 2017 642 $ 11.60 4.0 $ - Vested and expected to vest December 31, 2017 627 $ 11.50 3.8 $ - Exercisable at December 31, 2017 562 $ 10.70 3.3 $ - Option activity under the 2007 Plan for the year ended December 31, 2016, was as follows (in thousands, except as noted): Weighted Weighted- Average Average Remaining Aggregate Exercise Contractual Intrinsic Options Price Term Value (per share) (in years) Year Ended December 31, 2016 Outstanding at December 31, 2015 575 $ 10.50 5.3 $ 1,972 Granted 132 25.40 9.3 Exercised - - Forfeited - - Outstanding at December 31, 2016 707 $ 13.30 5.2 $ 2,241 Vested and expected to vest December 31, 2016 673 $ 12.70 5.0 $ 2,239 Exercisable at December 31, 2016 544 $ 10.10 4.1 $ 2,236
Warrant [Member]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	For stock options granted during 2017 and 2016 the following weighted average assumptions were used in determining fair value: 2017 2016 Risk-free interest rate 2.06 % 1.37 % Expected volatility 99 % 109 % Expected term in years 6.1 6.1 Dividend yield - % - %

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Derivative Financial Instruments Indexed to, and Potentially Settled in, Entity's Own Stock [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights	A summary of warrants outstanding and exercisable as of December 31, 2017 (in thousands, except as noted): Warrants Outstanding Warrants Exercisable Weighted Average Weighted Weighted Remaining Average Average Number Contractual Exercise Number Exercise Year Issued Outstanding Life Price Exercisable Price (in years) (per share) (per share) 2008 1 0.3 $ 9.00 1 $ 9.00 2014 25 1.1 47.40 25 47.40 2016 (Note 10) 128 4.0 23.30 128 23.30 2017 (Note 10) 1,124 4.7 $ 5.10 1,108 5.10 1,278 4.5 $ 7.70 1,262 $ 7.80

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Remaining Lease Payments Due Under Lease	A summary of future payments under operating leases as of December 31, 2017: For the Year (in thousands) 2018 116 2019 61 Total $ 177

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The components of the Company’s deferred tax asset are as follows: December 31, 2017 2016 (in thousands) Deferred tax assets – non-current Accrued bonuses $ - $ - Accrued vacation 17 32 Net operating loss (NOL) carryover 7,516 9,166 Technology licenses amortization 36 60 Research & development tax credits 1,542 1,259 Share based expense 387 443 Other 5 9 Fixed asset depreciation 15 - Total deferred tax asset 9,518 10,969 Less: valuation allowance (9,518) (10,965) Net deferred tax asset - 4 Deferred tax liability- non-current - (4) Net deferred tax asset $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	Reconciliation between income taxes at the statutory tax rate ( 34 December 31, 2017 2016 2015 (in thousands) Loss before income taxes $ (7,023) $ (6,750) $ (5,467) Tax (benefit) statutory tax rate (2,388) (2,295) (1,859) Effects of: Exclusion of incentive stock option expense 86 117 89 R&D tax credits (283) (252) (132) Increase (decrease) in valuation allowance (1,447) 3,001 1,899 FMV of warrants (658) (582) - Prior year adjustments 5 6 - Carryforward adjustment (252) 5 3 Rate change on net deferred tax asset 4,937 - - Provision for income taxes $ - $ - $ -

Organization and Business - Add

Organization and Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 08, 2018	Nov. 03, 2017	May 21, 2017	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Jun. 13, 2017	Dec. 31, 2015
Organization and Nature of Operations [Line Items]
Cash							$ 5,965	$ 9,375		$ 8,854
Stock issued during period, shares, new issues				588,235	588,235
Stock issued during period, value, new issues							3,567	$ 4,388
Proceeds from issuance initial public offering					$ 9,300
Proceeds from Warrant Exercises			$ 1,500
Class Of Warrant Or Right Exercisable Number			441,176
Stockholders' Equity, Reverse Stock Split	1-for-10
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements							(175)
Class Of Warrant Or Right Exercised Number			11,176
New Warrants [Member]
Organization and Nature of Operations [Line Items]
Proceeds from Warrant Exercises			$ 1,500
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 6
Warrants 2016 [Member]
Organization and Nature of Operations [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									127,941
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements							200
Extinguishment of Debt, Amount							400
Warrants2014 [Member]
Organization and Nature of Operations [Line Items]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings							$ 1,000
Reduced Exercise Price [Member]
Organization and Nature of Operations [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			3.80
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.80
Class Of Warrant Or Right Exercised Number			430,000
Warrant
Organization and Nature of Operations [Line Items]
Stock issued during period, shares, new issues				294,118	294,118
Stock issued during period, value, new issues					$ 10,000	$ 25,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 23
2016 Registered Direct Offering
Organization and Nature of Operations [Line Items]
Debt Issuance Costs, Net					$ 300
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					25,000
Registered Direct Offering 2017 [Member]
Organization and Nature of Operations [Line Items]
Stock issued during period, shares, new issues		1,333,333
Stock issued during period, value, new issues		$ 4,000
Proceeds from issuance initial public offering		$ 3,600
Registered Direct Offering 2017 [Member] | Warrant
Organization and Nature of Operations [Line Items]
Stock issued during period, shares, new issues		666,667
Roth Capital Partners, Llc [Member] | Registered Direct Offering 2017 [Member] | Warrant
Organization and Nature of Operations [Line Items]
Stock issued during period, shares, new issues		16,000

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Addtional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Other Intangible Assets, Net		$ 900,000
Other Finite-Lived Intangible Assets, Gross		2,500,000
Cash	$ 5,965,000	9,375,000	$ 8,854,000
Depreciation	251,000	43,000
Research and Development Costs Expenses	5,500,000	5,500,000
Amortization	$ 160,000	$ 161,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	562,041	544,167
Net Income Loss	$ (7,023,000)	$ (6,750,000)
Retained Earnings (Accumulated Deficit), Total	$ (39,157,000)	$ (32,134,000)
Warrant
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,277,784	595,118
Furniture and fixtures
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Computers and equipment
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Scientific equipment
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Leasehold improvements
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or lease term
Preclinical Stage Biotechnology Company
Significant Accounting Policies [Line Items]
Development Project Service Evaluation Exchange Cost	$ 50,000
Technology Services Revenue	50,000
Jp Morgan Chase Bank
Significant Accounting Policies [Line Items]
Cash, FDIC Insured Amount	5,700,000	$ 9,100,000
Federal Deposit Insurance	250,000
Cash		9,400,000
Md Anderson
Significant Accounting Policies [Line Items]
Other Intangible Assets, Net	800,000
Other Finite-Lived Intangible Assets, Gross	2,500,000
Amortization of Intangible Assets	1,700,000
Technology Amortization Annually	$ 200,000	$ 200,000

Prepaid Drug Product for Test32

Prepaid Drug Product for Testing - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Prepaid Drug Product For Testing [Line Items]
Prepaid drug product for testing	$ 1.1	$ 0.4

Other Current Assets- Additiona

Other Current Assets- Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Assets Current	$ 353	$ 902
Prepaid Insurance	100
Chronic Myelogenous Lleukemia [Member]
Other Assets Current	200
Prepaid Expenses [Member]
Other Assets Current	400	$ 900
Other Prepaid Expenses [Member]
Other Assets Current	$ 100

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross	$ 984	$ 708
Less accumulated depreciation	(330)	(94)
Net property and equipment	654	614
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	$ 432	393
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Computer And Office Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 63	77
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 46	46
Scientific Equipment [Member]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 443	$ 192

Accounts Payable - Additional I

Accounts Payable - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable [Line Items]
Accounts payable	$ 0.1	$ 0.1

Accrued Expense - Additional In

Accrued Expense - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	$ 739	$ 969
Accrued Vacation And Bonus	100	400
Accrued Laboratory Expense		200
Accrued Clinical And Preclinical	400	200
Accrued License Maintenance Fee	100	100
Other Accrued Liabilities	$ 100	$ 100

Warrant Liability - Additional

Warrant Liability - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jun. 13, 2017	Jul. 05, 2016
Warrant Liability [Line Items]
Derivative Liability, Fair Value, Gross Liability	$ 0	$ 2,900		$ 4,600
Increase (Decrease) in Derivative Liabilities	2,400	$ 1,700
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	(175)
Warrants 2016 [Member]
Warrant Liability [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			127,941
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	200
Extinguishment of Debt, Amount	$ 400
Health care Institutional Investors
Warrant Liability [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		294,118
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 23
Hc Wainwright Co Llc
Warrant Liability [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 24.60

Fair Value, Assets and Liabilit

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Noncurrent	$ 0	$ 2,906
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Noncurrent		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Noncurrent		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Noncurrent		$ 2,906

Fair Value Of Warrant Liability

Fair Value Of Warrant Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	$ 2,906	$ 0
Issuance		4,619
Change in fair value	(2,374)	(1,713)
Extinguished	(357)
Reclassified to equity	(175)
Balance	$ 0	$ 2,906

Fair Value Assumptions and Meth

Fair Value Assumptions and Methodology for Assets and Liabilities (Detail) - Warrant	Jun. 13, 2017	May 21, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk-free interest rate	1.51%	1.78%	1.93%
Expected volatility	88.00%	89.00%	98.00%
Expected term in years	4 years 7 months 6 days	4 years 7 months 6 days	5 years
Dividend yield	0.00%	0.00%	0.00%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Nov. 03, 2017	May 21, 2017	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shareholders Equity [Line Items]
Common stock and warrants issued, Value			$ 10,000
Common Stock, shares issued						11,339	9,564
Stock Issued During Period Shares New Issues			588,235	588,235
Stock Issued During Period, Value, New Issues						$ 3,567	$ 4,388
Stockholders Equity						$ 8,067	$ 8,240	$ 9,818
Proceeds from Issuance Initial Public Offering				$ 9,300
ClassOfWarrantOrRightExercisableNumber		441,176
Class Of Warrant Or Right Exercised Number		11,176
Proceeds from Warrant Exercises		$ 1,500
New Warrants [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6
Proceeds from Warrant Exercises		$ 1,500
Reduced Exercise Price [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.80
Class Of Warrant Or Right Exercised Number		430,000
Registered Direct Offering 2017 [Member]
Shareholders Equity [Line Items]
Stock Issued During Period Shares New Issues	1,333,333
Stock Issued During Period, Value, New Issues	$ 4,000
Proceeds from Issuance Initial Public Offering	$ 3,600
Warrant
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 23
Stock Issued During Period Shares New Issues			294,118	294,118
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		250,000
Stock Issued During Period, Value, New Issues				$ 10,000	$ 25,000
Warrant | Registered Direct Offering 2017 [Member]
Shareholders Equity [Line Items]
Stock Issued During Period Shares New Issues	666,667
Roth Capital Partners, Llc [Member] | Warrant | Registered Direct Offering 2017 [Member]
Shareholders Equity [Line Items]
Stock Issued During Period Shares New Issues	16,000
Placement Agent
Shareholders Equity [Line Items]
Common stock and warrant issued, shares			25,000

Weighted Average Assumptions (D

Weighted Average Assumptions (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation Plans [Line Items]
Risk-free interest rate	2.06%	1.37%
Expected volatility	99.00%	109.00%
Expected term in years	6 years 1 month 6 days	6 years 1 month 6 days
Dividend yield	0.00%	0.00%

Option Activity Under Plan (Det

Option Activity Under Plan (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Plans [Line Items]
Weighted Average Remaining Contractual Term (In years), Outstanding	2 years 3 months 18 days	5 years 2 months 12 days
Employee Stock Option [Member]
Share Based Compensation Plans [Line Items]
Outstanding	707	575
Granted	68	132
Forfeited	(87)	0
Expired	(46)
Exercised		0
Outstanding	642	707	575
Vested and expected to vest	627	673
Exercisable	562	544
Weighted - Average Exercise Price, Outstanding	$ 11.6	$ 10.5
Weighted - Average Exercise Price, Granted	7.5	25.4
Weighted - Average Exercise Price, Forfeited	16.50	0
Weighted - Average Exercise Price,Expired	21.30
Weighted - Average Exercise Price, Exercised		0
Weighted - Average Exercise Price, Outstanding	13.3	11.6	$ 10.5
Weighted - Average Exercise Price, Vested and expected to vest	11.5	12.7
Weighted - Average Exercise Price, Exercisable	$ 10.7	$ 10.1
Weighted Average Remaining Contractual Term (In years), Outstanding	4 years	5 years 2 months 12 days	5 years 3 months 18 days
Weighted Average Remaining Contractual Term (In years), Granted	9 years 3 months 18 days	9 years 3 months 18 days
Weighted Average Remaining Contractual Term (In years), Vested and expected to vest	3 years 9 months 18 days	5 years
Weighted Average Remaining Contractual Term (In years), Exercisable	3 years 3 months 18 days	4 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 1,972
Aggregate Intrinsic Value, Outstanding	2,241	0	$ 1,972
Aggregate Intrinsic Value, Vested and expected to vest	0	2,239
Aggregate Intrinsic Value, Exercisable	$ 0	$ 2,236

Stock-Based Compensation Plans

Stock-Based Compensation Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock Based Compensation Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6	$ 20.90
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 0.9
Stock-based compensation expense	$ 0.8	$ 0.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 3 months 18 days	5 years 2 months 12 days
Research and Development Expense
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense	$ 0.3	$ 0.4
General and Administrative Expense
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense	$ 0.5	$ 0.4
2007 Stock Incentive Plan
Stock Based Compensation Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,200,000

Warrants Outstanding and Exerci

Warrants Outstanding and Exercisable (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number Outstanding | shares	1,278
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 6 months
Warrants Outstanding, Weighted Average Exercise Price (per share) | $ / shares	$ 7.70
Warrants Exercisable, Number Exercisable | shares	1,262
Warrants Exercisable, Weighted Average Exercise Price (per share) | $ / shares	$ 7.80
Warrants 2014 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number Outstanding | shares	25
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 1 month 6 days
Warrants Outstanding, Weighted Average Exercise Price (per share) | $ / shares	$ 47.40
Warrants Exercisable, Number Exercisable | shares	25
Warrants Exercisable, Weighted Average Exercise Price (per share) | $ / shares	$ 47.40
Warrants 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number Outstanding | shares	128
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years
Warrants Outstanding, Weighted Average Exercise Price (per share) | $ / shares	$ 23.30
Warrants Exercisable, Number Exercisable | shares	128
Warrants Exercisable, Weighted Average Exercise Price (per share) | $ / shares	$ 23.30
Warrants 2008 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number Outstanding | shares	1
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	3 months 18 days
Warrants Outstanding, Weighted Average Exercise Price (per share) | $ / shares	$ 9
Warrants Exercisable, Number Exercisable | shares	1
Warrants Exercisable, Weighted Average Exercise Price (per share) | $ / shares	$ 9
Warrants 2017 [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding, Number Outstanding | shares	1,124
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)	4 years 8 months 12 days
Warrants Outstanding, Weighted Average Exercise Price (per share) | $ / shares	$ 5.10
Warrants Exercisable, Number Exercisable | shares	1,108
Warrants Exercisable, Weighted Average Exercise Price (per share) | $ / shares	$ 5.10

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended
	Apr. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Product Liability Contingency [Line Items]
Operating Leases, Future Minimum Payments Due		$ 177,000
Other Prepaid Expense, Current		1,100,000	$ 400,000
Other Commitment, Due in Next Twelve Months		1,200,000
Drug Supplier Project Plan [Member]
Product Liability Contingency [Line Items]
Other Commitment		1,600,000
Manufacturer Of Prexigebersen [Member]
Product Liability Contingency [Line Items]
Other Commitment		1,000,000
Manufacture Of Drug Substance [Member]
Product Liability Contingency [Line Items]
Other Commitment		400,000
Manufacturing Development [Member]
Product Liability Contingency [Line Items]
Other Commitment		200,000
Office Space [Member]
Product Liability Contingency [Line Items]
Operating Leases, Future Minimum Payments Due		100,000
Lab Space [Member]
Product Liability Contingency [Line Items]
Operating Lease Monthly Rental Payments	$ 2,500
Licenses Agreement
Product Liability Contingency [Line Items]
Accounts payable and accrued liabilities		$ 100,000

Schedule of future payments und

Schedule of future payments under operating leases (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Operating Leased Assets [Line Items]
2,018	$ 116
2,019	61
Total	$ 177

Benefit Plan - Additional Infor

Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation	$ 47,000	$ 48,000
General Discussion of Pension and Other Postretirement Benefits	We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of each employee’s base salary up to the allowable amount which is fully vested on the date the matching contributions are made.

Income Taxes - Addtional Inform

Income Taxes - Addtional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Operating Loss Carryforwards		$ 35,800
Deferred Tax Assets, Tax Credit Carryforwards, Research		1,542	$ 1,259
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		$ (1,447)	3,001	$ 1,899
Research And Development Tax Credit Carryforward, Expiration Period		2028 years
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 4,900
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		9,500	$ 11,000
Scenario, Plan [Member]
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Research and Development Expense [Member]
Income Tax [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Research		$ 1,500
Minimum [Member]
Income Tax [Line Items]
Operating Loss Carry forwards Expiration Period		2,026

Components Of Companys Deferred

Components Of Companys Deferred Tax Asset (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets-non current
Accrued bonuses	$ 0	$ 0
Accrued vacation	17	32
Net operating loss (NOL) carryover	7,516	9,166
Technology licenses amortization	36	60
Research & development tax credits	1,542	1,259
Share based expense	387	443
Other	5	9
Fixed asset depreciation	15	0
Total deferred tax asset	9,518	10,969
Less: valuation allowance	(9,518)	(10,965)
Net deferred tax asset	0	4
Deferred tax liability- non current	0	(4)
Net deferred tax asset	$ 0	$ 0

Reconciliation Between Income T

Reconciliation Between Income Taxes at Statutory Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]
Loss before income taxes	$ (7,023)	$ (6,750)	$ (5,467)
Tax (benefit) @ statutory tax rate	(2,388)	(2,295)	(1,859)
Effects of:
Exclusion of incentive stock option expense	86	117	89
R&D tax credits	(283)	(252)	(132)
Increase (decrease) in valuation allowance	(1,447)	3,001	1,899
FMV of warrants	(658)	(582)	0
Prior year adjustments	5	6	0
Carryforward adjustment	(252)	5	3
Rate change on net deferred tax asset	4,937	0	0
Provision for income taxes	$ 0	$ 0	$ 0

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail)	Feb. 08, 2018
Subsequent Event [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-10
Subsequent Event [Member]
Subsequent Event [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-10